Tissue engineering offers significant promise as a viable alternative to current clinical strategies for replacement of damaged tissue as a consequence of disease or trauma.
In recent years, new insights into the molecular and biochemical mechanism(s) of fuel-mediated insulin release coupled with advances in gene transfer technology have led to the investigation of molecular strategies for replacement of normal insulin delivery function.
It is significant to develop a strategy for maintenance, replacement and design changes related to those subsystems and components.
Further study to refine the processes and generate larger quantities of engineered tissue will be necessary in order to employ tissue-engineered intestine as a viable future strategy for intestinal replacement in patients with intestinal failure.
The high degree of stem cell plasticity provides a promising strategy for cell replacement therapy.
The use of mRNA-based gene transfer could be a new promising strategy for transcript replacement and vaccination therapy.
These studies provide evidence that genetic reprogramming of expandable human pancreatic cells with defined factors may serve as a general strategy for islet replacement in diabetes.
We believe that further investigation into the mechanism is warranted before we plan a successful strategy for corticosteroid replacement in sepsis.
See related research by Friedrich et al., http://www.ccforum.com/content/16/4/R146 The strategy for renal replacement therapy (RRT) in patients with acute kidney injury (AKI) remains controversial.
Owing to scarcity of liver donors, which hampers both transplantation of whole organs and of cell suspensions, transplantation of hepatic stem/progenitor cells (HSPCs) has been explored as a valuable bridge and legitimate, alternate strategy for whole-organ replacement.
In particular, this strategy will allow for replacement of the catalytic His57 residue and the buried N-terminus, which is thought to help align the active site, with synthetic analogs.
